Immunovant Inc
For the period ended Mar 31, 2025. Filed May 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
On February 14, 2025, Douglas Hughes, amember of our Board of Directors, adopted a trading plan for the sale of a maximum of 15,000 shares of our common stock (the “Trading Plan”) for the purpose of satisfying applicable tax obligations arising in connection with the vesting and settlement of restricted stock units. The Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and is expected to remain in effect until December 15, 2025, or upon the earlier completion of all authorized transactions thereunder.
None of our other directors or Section 16 reporting officers adopted, modified orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC’s Regulation S-K) during the three months ended March 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.